Journal of Cancer Research and Immuno-Oncology

OPEN ACCESS Freely available online

Commentary

Antigen Presentation Breakdown: Cancer Hides in Plain Sight

Ellis Tadeo*

Department of Immunology, University of Melbourne, Melbourne, Australia

DESCRIPTION

The immune system relies on a delicate choreography of recognition and response to defend the body against pathogens and abnormal cells. Central to this defense is the process of antigen presentation a cellular mechanism that allows immune cells, particularly T cells, to detect and target abnormal or malignant cells. However, cancer has evolved sophisticated ways to evade this detection, effectively "hiding in plain sight." Understanding antigen presentation breaks down in tumors is crucial not only for comprehending cancer biology but also for developing therapies that restore the immune system's ability to recognize and destroy malignant cells.

Antigen presentation is essentially the immune system's surveillance system. Cells display fragments of proteins, known as antigens, on their surface via molecules called Major Histocompatibility Complex (MHC) proteins. Cytotoxic T Lymphocytes (CTLs) monitor these displays, ready to eliminate any cell showing abnormal or foreign peptides. this process functions correctly, it serves as a first line of defense against cancer, viral infection, and other cellular dysfunctions. Yet cancer cells often exploit weaknesses in this system, manipulating antigen presentation pathways to avoid immune detection entirely.

The mechanisms of immune evasion

One of the primary ways cancer "hides in plain sight" is by downregulating MHC class I molecules, are essential for presenting intracellular antigens to T cells. Without these molecules, T cells cannot recognize tumor-associated antigens, effectively making the cancer cell invisible to one of the body's most potent anti-cancer mechanisms. Tumors may also mutate components of the antigen processing machinery, such as TAP (Transporter Associated Antigen Processing) proteins, further preventing the proper display of antigens. In essence, the cancer cell is sabotaging the immune system's radar, turning should be a clear signal of danger into silence.

The consequences of this breakdown are profound. Tumors that evade T-cell detection tend to progress more aggressively and resist immunotherapies that rely on antigen recognition, such as checkpoint inhibitors. Even these therapies unleash T cells from inhibitory signals, the absence of visible antigens leaves T cells with no targets to attack. This phenomenon contributes to the variable success of immunotherapy across different cancer types and patients. For example, cancers such as pancreatic adenocarcinoma or certain lung tumors often show low MHC expression, making them particularly challenging to treat with T-cell–based approaches.

Interestingly, the immune system is not completely helpless. Natural Killer (NK) cells, a distinct population of cytotoxic lymphocytes, are programmed to target cells that lack MHC class I molecules. This complementary surveillance mechanism means that the immune system has built-in redundancies to compensate for antigen presentation failures. Nonetheless, tumors often create an immunosuppressive microenvironment that impairs NK cell activity, illustrating the multiple layers of evasion that cancer can employ.

Therapeutic strategies to expose hidden cancer

Recognizing tumors avoid antigen presentation has prompted researchers to develop innovative strategies to counteract this stealth behavior. One approach focuses on restoring or enhancing antigen presentation in cancer cells. Epigenetic therapies, inhibitor of deoxyribonucleic acid methyltransferases or histone deacetylases, can reactivate genes involved in MHC expression, effectively making cancer cells "visible" to T cells once again. Similarly, cytokine therapies, including interferons, can upregulate MHC class I molecules and other components of the antigen presentation pathway, boosting the likelihood that the immune system will detect malignancy.

Another promising avenue involves bypassing the need for antigen presentation entirely. NK cell therapies, chimeric NK cell and other innate immune cell–based treatments can target tumor cells independently of MHC display, reducing reliance on T-cell recognition. Additionally, bispecific antibodies or engineered immune cells can bridge immune effector cells directly to cancer cells, circumventing traditional antigen presentation mechanisms. These strategies reflect a broader shift in immuno-oncology rather than relying solely on natural

Correspondence to: Ellis Tadeo, Department of Immunology, University of Melbourne, Melbourne, Australia, Email: tadeo@gmail.com

Received: 26-Nov-2025, Manuscript No. JCRIO-25-39442; **Editor assigned:** 28-Nov-2025, PreQC No. JCRIO-25-39442 (PQ); **Reviewed:** 12-Dec-2025, QC No. JCRIO-25-39442; **Revised:** 19-Dec-2025, Manuscript No. JCRIO-25-39442 (R); **Published:** 26-Dec-2025, DOI: 10.35248/2684-1266.25.11.275

Citation: Tadeo E (2025). Antigen Presentation Breakdown: Cancer Hides in Plain Sight. J Cancer Res Immunooncol. 11: 275

recognition pathways, therapies can now be designed to actively expose or attack tumors regardless of their evasive tactics.

Combination therapies are increasingly emerging as the most effective approach. By pairing treatments that restore antigen presentation with checkpoint inhibitors or adoptive cell therapies, clinicians can create a multi-layered assault on tumors. Early clinical trials suggest that these combinations can convert "cold" tumors those hidden from the immune system into "hot" tumors, immune cells infiltrate and attack effectively. This dual approach addresses the root cause of immune evasion simultaneously amplifying the immune response, offering hope for patients cancers were previously considered resistant to immunotherapy.

CONCLUSION

Antigen presentation breakdown exemplifies cancer's ability to exploit the body's own regulatory systems for survival. By understanding the molecular tricks that tumors use to hide, scientists are now designing therapies that restore visibility, enhance immune recognition, and leverage alternative pathways for destruction. The fight against cancer is increasingly a battle of visibility the more we can reveal the tumor's presence, the more effectively we can mobilize the immune system to respond. As immunotherapies continue to evolve, overcoming antigen presentation defects will remain a central challenge and a vital opportunity to turn cancer's stealth strategies against itself.